|Bid||1.5200 x 38500|
|Ask||1.5300 x 43500|
|Day's range||1.4400 - 1.6100|
|52-week range||1.2100 - 9.5400|
|Beta (5Y monthly)||3.13|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.07|
Aurora Cannabis' (NASDAQ: ACB) stock had ratcheted upward by more than 8.1% on Friday at 10:11 a.m. ET after a Cantor Fitzgerald analyst, Pablo Zuanic, adjusted his outlook on the company from neutral to overweight, citing its favorable positioning within the rapidly growing European cannabis market. The upgrade is a welcome reprieve for shareholders, as analysts have overwhelmingly rated Aurora as a hold rather than a buy this year, with a few recommending to sell. The analyst's new outlook is surprising, considering that over the last year, Aurora's quarterly revenue has fallen by more than 10.8%, its total quarterly expenses have risen by above 13.1%, and its quarterly revenue as a proportion of expenses has risen sharply.
Shares of Aurora Cannabis (NASDAQ: ACB) crumbled by more than 11.7% on Monday as of noon ET amid a widespread decline in markets stemming from inflation concerns and the associated actions to control it as implemented by the Federal Reserve. Growth stocks are being hit particularly hard by the downturn, and to add insult to injury, cannabis stocks haven't been performing well in at least a year, with the industry-tracking AdvisorShares Pure US Cannabis ETF falling by more than 66.6% in the last 12 months. Aurora has issues that this decline will make worse, starting with being unprofitable and needing more cash.
Canadian pot company Aurora Cannabis (NASDAQ: ACB) has been on a downward spiral for the last two years. Let's dig into why this pot stock would make a sour investment now. Nothing seems to be different for Aurora Cannabis this year.